De snelle ontwikkeling van reagentia voor het detecteren van belangrijke mutaties blijft kritische onderzoeks- en monitoring activiteiten vergemakkelijken

SYDNEY–(BUSINESS WIRE)– SpeeDx Pty. Ltd., een ontwikkelaar van innovatieve moleculaire diagnostische oplossingen, heeft zijn productlijn van onderzoeksreagentia voor de analyse van COVID-19-varianten verder uitgebreid met een belangrijke karakteristieke mutatie die verband houdt met de SARS-CoV-2 Lambda variant of interest (VOI). De PlexPrime® SARS-CoV-2 Genotyping-productlijn is sinds de lancering in juli snel uitgebreid, gebruikmakend van de unieke universele substraat benadering en gepatenteerde multiplex technologie van het bedrijf. De reeks producten kan onafhankelijk of gecombineerd worden gebruikt om laboratoriumonderzoek en monitoring van belangrijke SARS-CoV-2-varianten van belang of zorg te ondersteunen.

Dit persbericht bevat multimedia. Bekijk de volledige release hier: https://www.businesswire.com/news/home/20211005006261/en/

SpeeDx Build Further Coverage in SARS-CoV-2 Genotyping Reagent Portfolio

Rapid development of key mutation detection reagents continues to facilitate critical investigation and monitoring activities

SYDNEY–(BUSINESS WIRE)– SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, have further expanded their product line of research reagents for COVID-19 variant analysis to include a key characteristic mutation connected to the SARS-CoV-2 Lambda variant of interest (VOI). The PlexPrime® SARS-CoV-2 Genotyping* product line has rapidly expanded since launching in July, utilising the company’s unique universal substrate approach and patented multiplexing technology. The suite of products can be used independently or combined to support laboratory investigation and monitoring efforts of key SARS-CoV-2 variants of interest or concern.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211005006261/en/

PlexPrime® SARS-CoV-2 L452Q Lambda* is a single well mix designed to detect the L452Q spike mutation of SARS-CoV-2 found in the C.37 variant of interest (Lambda)1, in addition to an RdRp gene target of SARS-CoV-2. This reagent is the third product in the PlexPrime® SARS-CoV-2 Genotyping portfolio and can be used as a stand-alone reflex or combined with PlexPrime® SARS-CoV-2 Alpha/Beta/Gamma+, and/or the PlexPrime®P681R Delta reagents. (Photo: Business Wire)

“Rapid screening of positive samples with a PCR-based approach allows laboratories to easily monitor mutations as they circulate” said Dr Charles Cartwright, SpeeDx Senior Vice President of Clinical Affairs. “The individual mutations targeted with our suite of genotyping reagents have been carefully chosen to represent key lineage divergence, thus we are finding that even the latest emerging variants of interest and concern can be targeted for further analysis with our existing portfolio.”

PlexPrime® SARS-CoV-2 L452Q Lambda* is a single well mix designed to detect the L452Q spike mutation of SARS-CoV-2 found in the C.37 variant of interest (Lambda)¹, in addition to an RdRp gene target of SARS-CoV-2. This reagent is the third product in the PlexPrime® SARS-CoV-2 Genotyping portfolio and can be used as a stand-alone reflex or combined with PlexPrime® SARS-CoV-2 Alpha/Beta/Gamma+, and/or the PlexPrime®P681R Delta reagents. Compatible with standard qPCR and liquid handling instrumentation, the PlexPrime® SARS-CoV-2 Genotyping will reduce the costs and manual processes for laboratories currently practicing high-volume sequence analysis.

About SpeeDx

Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see: https://plexpcr.com

*available as Research Use Only reagents not for use in diagnostic procedures

References

1. Tracking SARS-CoV-2 variants. World Health Organisation. Found at: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/

View source version on businesswire.com: https://www.businesswire.com/news/home/20211005006261/en/

Contacts

Madeline O’Donoghue – SpeeDx Global Marketing Director

madelineo@speedx.com.au
+61 406 582 808